Zevra Therapeutics (ZVRA) Total Liabilities (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Total Liabilities came in at $72.8 million in Q1 2026, down 44.74% YoY from $131.7 million in Q1 2025, and down 44.05% on a QoQ basis from $130.1 million in Q4 2025.
Zevra Therapeutics (ZVRA) Total Liabilities (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Total Liabilities data on file, last reported at $72.8 million in Q1 2026.
- Quarterly Total Liabilities fell 44.74% year-over-year to $72.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.8 million (down 44.74% YoY) and the FY2025 annual result came in at $130.1 million, down 6.06% from the prior year.
- Total Liabilities declined to $72.8 million in Q1 2026, from $130.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $139.0 million in Q2 2025 to a low of $4.2 million in Q1 2022.
- A 5-year average of $84.5 million and a median of $102.5 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities sank 72.99% — and 2024, when it soared 1063.03%.
- Tracing ZVRA's Total Liabilities over 5 years: stood at $40.2 million in 2022, then soared by 174.65% to $110.5 million in 2023, then climbed by 25.35% to $138.5 million in 2024, then slipped by 6.06% to $130.1 million in 2025, then plunged by 44.05% to $72.8 million in 2026.
- The last three Total Liabilities figures came in at $72.8 million (Q1 2026), $130.1 million (Q4 2025), and $137.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 85.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.06 Mn |
| Mar 31, 2026 | 72.78 Mn |
| Dec 31, 2025 | 130.07 Mn |
| Sep 30, 2025 | 136.95 Mn |
| Jun 30, 2025 | 139.05 Mn |
| Mar 31, 2025 | 131.69 Mn |
| Dec 31, 2024 | 138.46 Mn |
| Sep 30, 2024 | 121.78 Mn |
| Jun 30, 2024 | 111.93 Mn |
| Mar 31, 2024 | 102.47 Mn |
| Dec 31, 2023 | 110.46 Mn |
| Sep 30, 2023 | 77.46 Mn |
| Jun 30, 2023 | 9.62 Mn |
| Mar 31, 2023 | 47.33 Mn |
| Dec 31, 2022 | 40.22 Mn |
| Sep 30, 2022 | 25.76 Mn |
| Jun 30, 2022 | 35.64 Mn |
| Mar 31, 2022 | 4.21 Mn |
| Dec 31, 2021 | 5.82 Mn |
| Sep 30, 2021 | 5.45 Mn |